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Abstract
Background and objectives
In dialysis patients, there is an increasing evidence that altered bone metabolism is associ-
ated with cardiovascular calcifications. The main objective of this study was to analyse, in
hemodialysis patients, the relationships between bone turnover, mineralization and volume,
evaluated in bone biopsies, with a plain X-ray vascular calcification score.
Design, setting, participants and measurements
In a cross-sectional study, bone biopsies and evaluation of vascular calcifications were per-
formed in fifty hemodialysis patients. Cancellous bone volume, mineralized bone volume,
osteoid volume, activation frequency, bone formation rate/bone surface, osteoid thickness
and mineralization lag time were determined by histomorphometry. Vascular calcifications
were assessed by the simple vascular calcification score (SVCS) in plain X-Ray of pelvis
and hands and, for comparison, by the Agatston score in Multi-Slice Computed Tomography
(MSCT).
Results
SVCS3 was present in 20 patients (40%). Low and high bone turnover were present in
54% and 38% of patients, respectively. Low bone volume was present in 20% of patients. In
multivariable analysis, higher age (p = 0.015) and longer hemodialysis duration (p = 0.017)
were associated with SVCS3. Contrary to cancellous bone volume, the addition to this
model of mineralized bone volume (OR = 0.863; 95%CI: 0.766, 0.971; p = 0.015), improved
the performance of the model. For each increase of 1% in mineralized bone volume there
was a 13.7% decrease in the odds of having SVCS3 (p = 0.015). An Agatston score>400
was observed in 80% of the patients with a SVCS3 versus 4% of patients with a SVCS<3,
(p<0.001).
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Conclusion
Higher mineralized bone volume was associated with a lower plain X-ray vascular calcifica-
tion. This study corroborates the hypothesis of the existence of a link between bone and
vessel and reinforces the clinical utility of this simple and inexpensive vascular calcification
score in dialysis patients.
Introduction
Vascular calcifications are associated with cardiovascular morbidity and mortality in dialysis
patients [1–4]. It has been demonstrated that vascular calcification in dialysis and non-dialysis
patients is an active cellular process, similar to bone formation [5–7]. In an experimental
model, high levels of phosphorus and calcium [5] are some of the factors that activate the core
binding factor α-1 (Cbfa-1), which is the first step for the differentiation of vascular smooth
muscle cells into osteoblasts [5]. Reduction of calcification inhibitors, such as Fetuin-A,
matrix-Gla protein [8] and pyrophosphate [9,10] may be another factor associated with the
development of calcification. In dialysis patients, there is increasing evidence that altered bone
metabolism is associated with cardiovascular calcifications.
KDIGO has recommended in 2006 a new classification for mineral and bone disorders of
chronic kidney disease that includes the presence of vascular calcifications [11]. Low bone
turnover [12–14] and low bone volume [15] have been associated with vascular calcifications.
Adynamic bone disease [13] and osteoporosis have been associated with progression of coro-
nary calcifications [16]. An association between osteoporotic fractures, vascular calcifications
and mortality has been demonstrated in dialysis patients [17]. We have developed a simple
vascular calcification score (SVCS) evaluated in plain X-Ray of pelvis and hands, which is a
predictor of cardiovascular mortality and cardiovascular disease in dialysis patients [3,18,19]
and in CKD patients not on dialysis [20]. The main objective of this study was to evaluate, in
dialysis patients, relationships between histomorphometric parameters of bone turnover, min-
eralization and volume with this simple vascular calcification score. The secondary objective
was to evaluate, in the same patients, the agreement between the SVCS and the Agatston score
obtained by multislice computed tomography (MSCT).
Material and methods
Study design
This is a cross-sectional study performed in a group of prevalent hemodialysis patients to eval-
uate relationships between histomorphometric parameters of bone, evaluated by bone biopsy,
with vascular calcifications evaluated by plain X-ray (SVCS). This is an extension study per-
formed in a cohort of 50 patients participating in a European randomized clinical trial, with
the Study Number: GTC-68-402, that analysed the effect of sevelamer hydrochloride and cal-
cium carbonate on bone turnover and mineralization in hemodialysis patients [21], (Fig 1).
This randomized clinical trial was a requisition of EMA (European Medicines Agency) and
was initiated in 2002. This trial has no registration number because The European Clinical Tri-
als Register started after 1 May 2004 with the creation of EdraCT.
Our present study was an extension study from this clinical trial and included a group of 50
patients that accepted undergo evaluation of vascular calcifications in the same diagnostic cen-
ter, in Lisbon, immediately after the second bone biopsy performed in the clinical trial. The
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protocol of this study was approved by the institutional ethical committees of the hemodialysis
units participating in the study (FMC Entroncamento, Torres Vedras and Barreiro; CMDR,
Fig 1. The intention-to-treat (ITT) population was defined as all patients who were randomly assigned, received one or more doses of study
medication, and had a second bone biopsy. One patient in the sevelamer group completed treatment but did not have a second bone biopsy and so was
excluded from the ITT analysis. Two patients in the calcium group withdrew from the study early but received one or more doses of study medication and
had a second bone biopsy and so were included in the ITT analysis.
https://doi.org/10.1371/journal.pone.0179868.g001
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Centro Me´dico de Doenc¸as Renais, HPA, Hospital Particular Almada, SPD, Sociedade Portu-
guesa de Dia´lise, Uninefro, Santo Tirso and NefroNorte, Paredes). All patients signed an
informed consent, and all the studies procedures were in accordance with the recommenda-
tions for research involving human beings of the Helsinqui Declaration (with the amendments
of Tokyo 1975, Hong-Kong 1989, Somerset West 1996 and Edimburg 2000) and of the WHO).
Assessment of vascular calcifications
Vascular calcifications were assessed by the simple vascular calcification score (SVCS), a semi-
quantitative score developed by us and evaluated in plain radiographs of pelvis and hands [3].
Pelvis films were divided into four sections by two imaginary lines: a horizontal line over the
upper limit of both femoral heads and a median vertical line over the vertebral column. A hori-
zontal line divided hand films over the upper limit of the metacarpal bones. In each section,
the presence of any type of vascular calcification lining the vessel walls, either in a linear or
irregular pattern, was rated as 1 and its absence as 0. Final score was the sum of calcifications
found in all sections and ranged from 0 to 8. In the same diagnostic centre, vascular calcifica-
tions were simultaneously assessed in 42 patients by the Agatston score, using Multislice Com-
puted Tomography (MSCT). MSCT scans were performed with the four-slice technique on
the model Somatom Volume Zoom (Siemens AG, Erlangen, Germany). Slices of 2.5 mm
thickness were acquired under the following conditions: 120 kVp, 130 mAs, and 0.5 gantry
rotation time. All images were transferred to a workstation and analysed with calcium scoring
software (HeartView CT, Siemens AG, Erlangen, Germany).
Plain X-Ray calcifications and coronary Agatston score were evaluated at the same diagnos-
tic center, 3.8 ±1.9 months after bone biopsy.
Bone biopsies and bone histomorphometry
All bone biopsies were performed in Lisbon (by A.F.) and Oporto (by J.M.F). Anterior iliac
crest bone biopsies were done after tetracycline double labelling under local anesthesia and
conscious sedation. The labelling schedule consisted of a 2 days oral administration of tetracy-
cline hydrochloride (250 mg twice daily) followed by a drug-free interval of 10 days, and subse-
quent oral administration of demeclocycline hydrochloride (300 mg twice daily) for 4 days.
Bone biopsies were performed 3 to 4 days after completing the second label. Bone samples
were obtained with the one-step electrical drill technique (Straumann Medical, Waldenburg,
Switzerland). All bone samples were processed and analysed at the Bone Diagnostic and
Research Laboratory, University of Kentucky, (Lexington, KY) without knowledge of the clini-
cal data.
Iliac crest bone samples were fixed in ethanol, dehydrated, and embedded in methylmetha-
crylate as previously described [22]. Serial sections of 3 and 7-micrometer thickness were cut
with a Microm microtome equipped with a carbide edged knife (HM360, Microm, Walldorf,
Germany). Sections were stained with the modified Masson-Goldner trichrome stain [23] and
for aluminium detection with the aurin tricarboxylic acid stain [24], and solochrome azurine
stain [25]. Unstained sections were prepared for phase contrast and fluorescent light micros-
copy. Histomorphometry for parameters of bone structure and bone remodelling was done
using the Osteoplan II system (C. Zeiss, NY) [26,27]. Bone turnover was determined by activa-
tion frequency (Ac.f) (Normal 0.49–0.72/year) and bone formation rate per bone surface
(BFR/BS) (Normal 1.8–3.8 mm3/cm2/year). Bone mineralization was evaluated by mineraliza-
tion lag time (Mlt) (Normal < 50 days) and osteoid thickness (O.Th) (Normal 4–20 μm). Bone
volume was evaluated as cancellous bone volume per tissue volume (BV/TV) (Normal 16–
23%), mineralized bone volume per tissue volume (Md.BV/TV) (Normal 13–21%) and osteoid
Mineralized bone volume and simple vascular calcification score in hemodialysis patients
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volume per bone volume (OV/BV) (Normal 0.57–6.00%). Bone histomorphometry nomencla-
ture and units are in agreement with the 2012 update report of the ASBMR histomorphometry
nomenclature committee [28]. Normal values are from American and European studies.
These values have been used in prior studies including histomorphometric assessment of bone
from patients of Portugal and other European countries and from the USA [15,21,29–34].
Biochemical analysis
Serum levels of the following biochemical parameters were evaluated and time averaged for
the 12 months preceding the bone biopsy: serum calcium, phosphorus, and iPTH were evalu-
ated every 4 weeks; bone specific alkaline phosphatase, 25-(OH)-vitamin D3; 1,25-(OH)2-vita-
min D3 and lipid profile were evaluated every 6 months; iPTH was evaluated using the DPC
Immulite PTH IRMA; the reference range is 25 to 87 pg/mL and the intra and inter-assay coef-
ficients of variation are<7% and<9%, respectively; 1,25-(OH)2-vitaminD3 and 25-(OH)-vita-
min D were analysed by radioimmunoassay using LIAISON kits (DiaSorin, Sallugia, Italy).
The reference range for 1,25-(OH)2-vitaminD3 was 25 to 86.5 pg/mL and the intra and inter-
assay coefficients of variation were<2.9% and<5.9%, respectively. The reference range for
25-(OH)-vitaminD3 was 25 to 100 ng/mL and the intra and inter-assay coefficients of variation
were 4.1% and 7% respectively. Total cholesterol, LDL-cholesterol, HDL-cholesterol and tri-
glycerides were measured every 4 months by the Synchron LX system (Beckman Coulter, Ful-
lerton, California).
Statistical analysis
An exploratory analysis was carried out for all variables. Categorical data were presented as fre-
quencies and percentages, and continuous variables as mean ± standard deviation or median
and inter-quartile range (25th percentile; 75th percentile). Univariable analysis was done using
Student´s t-test and nonparametric tests (Chi-square, Fisher’s Exact, Mann-Whitney U) when-
ever outliers and skewed distributions were present.
The multivariable analysis was performed using logistic regression models where the
dependent variable was SVCS after being dichotomized (SVCS<3 and SVCS3), according to
previously demonstrated association with cardiovascular mortality (3,18). To obtain a first
model (model 1), all the variables with a p-value<0.25 obtained in the univariable analysis and
with clinical relevance, were considered. To compare bone parameters regarding their associa-
tion with vascular calcifications measured by SVCS, three additional models were adjusted.
These models were obtained by adding to model 1, separately, the variables BV/TV (bone vol-
ume, model 2), Md.BV/TV (mineralized bone volume, model 3) and OV/BV (osteoid volume,
model 4). Bone volume consists of mineralized bone volume and osteoid volume.
To quantify the improvement resulting from adding BV/TV, (Model 2), Md.BV/TV
(Model 3) and OV/BV (Model 4) to Model 1, continuous net reclassification improvement
(NRI) and integrated discrimination improvement (IDI) measures were calculated [35,36]
(supplemental statistical analysis, S1 Table). Predictiveness curves were also calculated [37].
To study the agreement between SVCS and Agatston score, Spearman’s correlation coeffi-
cient was estimated. A further agreement analysis, considering both SVCS and Agatston scores
after being dichotomized, was performed and Cohen’s kappa was obtained with corresponding
bias corrected accelerated bootstrap 95% confidence intervals. The interpretation of kappa is
the following: values0 indicate no agreement, 0.01–0.20 slight, 0.21–0.40 fair, 0.41–0.60 mod-
erate, 0.61–0.80 substantial, and 0.81–0.99, almost perfect agreement [38,39]. In this analysis,
for Agatston score the cut-point 400 was considered [40]. For SVCS, the cut-point that best
discriminated lower (400) from higher Agatston scores (>400) was determined using
Mineralized bone volume and simple vascular calcification score in hemodialysis patients
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minimum p-value approach. Based on a systematic search for the best cut-point, the point that
is associated with the minimum chi-squared test p-value or, equivalently, with the maximum
chi-squared test value in a grid of marker values is identified [41]. Sensitivity, specificity, posi-
tive predictive value, and negative predicted value were calculated for the obtained cut-point.
Confidence intervals (95% CI) were also calculated, as required. The level of significance
α = 0.05 was considered.
All data were analyzed using SPSS 22.0 (IBM Corp. Released 2013. IBM SPSS Statistics for
Windows. Armonk, NY: IBM Corp) and R software (R: A Language and Environment for Sta-
tistical Computing, R Core Team, R Foundation for Statistical Computing, Vienna, Austria,
2014).
Results
Fifty patients (27 men and 23 women) from the above-mentioned randomized trial [21] were
enrolled, with a mean age of 53.52 ± 15.61 years and a median hemodialysis duration of 36.87
months (P25 = 25.95; P75 = 65.15). The only inclusion criterion for the present study was the
patient’s agreement to undergo evaluation of vascular calcifications in a single centre which
was performed at 3.8 ± 1.9 months after bone biopsies.
Phosphate binders were given during the year before bone biopsies either with sevelamer
hydrochloride in 26 patients, 52%; mean dose 4.1 ± 1.9 g/day or calcium carbonate in 24
patients, 48%; mean dose 3.7 ± 1.8 g/day. Twenty-nine patients (58%) were treated with active
vitamin D with a mean dose 3.8 ± 2.7 μg/week. Eight patients (16%) were smokers and five
(10%) were diabetic.
The demographic, biochemical, bone summary measures of the study sample and their
association with SVCS are presented in Tables 1 and 2, respectively. Vascular calcifications
were detected by plain X-ray in 30 patients (60%). Pelvic vascular calcifications were present in
29 patients (58%) and hand vascular calcifications were present in 16 patients (32%). SVCS3
was found in 20 patients (40%). Low and high bone turnover were present in 27 patients (54%)
and 19 patients (38%); there were no cases of osteomalacia. None of the bone biopsies showed
positive stain for aluminium.
Univariable analysis
Demographic, biochemical and vascular calcification univariable analysis results are shown in
Table 1. Among the variables with a p-value < 0.25, gender (p = 0.021), age (p = 0.030) and
diabetes (p = 0.007) were the factors associated with SVCS. In the group of patients with
SVCS3 (Table 1), 12 in 15 patients (80%) had an Agatston score >400 (p<0.001). Diabetes
had a very low prevalence in the study sample (n = 5; 10% with 0% in the group of patients
with SVCS<3), and was not included in the multivariable analysis. The variable gender was
also not included due to the low number of events in the female gender.
Results of bone parameters are shown in Table 2. Lower mineralized bone volume (p = 0.029)
was associated with a SVCS3. We found no association between cancellous bone volume, oste-
oid volume, osteoid thickness, mineralization lag time, bone formation rate, activation frequency
and high or low bone turnover with SVCS results.
Multivariable analysis
In the multivariable analysis (Table 3 and Fig 2), a first model (Model 1) was obtained where
older age (p = 0.015) and longer hemodialysis duration (p = 0.017) were associated with a
SVCS3. From all models presented in Table 3, with different bone volume variables, only min-
eralized bone volume, (p = 0.015) was independently associated with a SVCS3. Bone volume
Mineralized bone volume and simple vascular calcification score in hemodialysis patients
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consists of mineralized bone volume and osteoid volume. For each increase of 1% in mineral-
ized bone volume there was a 13.7% decrease in the odds of having SVCS3 (p = 0.015). The
addition of mineralized volume to Model 1 resulted in an increased performance of the model.
Table 1. Univariable analysis: Demographic, biochemical and vascular calcification parameters.
Variables All patients(n = 50) SVCS<3 (n = 30; 60%) SVCS3 (n = 20; 40%) p value
Age (years) 53.52 ± 15.61 49.63 ± 15.63 59.35 ± 14.00 0.030
Male gender n(%) 27 (54%) 12 (40%) 15 (75%) 0.021(a)
Diabetes n(%) 5 (10%) 0 (0%) 5 (25%) 0.007(b)
Smoking habits n(%) 8 (16%) 5 (17%) 3 (15%) 1.000(b)
HD duration (months) 36.87 (25.95; 65.15) 34.12 (25.80; 51.76) 44.72 (26.79; 93.13) 0.089 (c)
Hb (mg/dL) 12.57 ± 3.46 11.99 ± 1.00 12.96 ± 4.38 0.339
Ca (mg/dL) 9.56 ± 0.62 9.44 ± 0.51 9.73 ± 0.74 0.111
P (mg/dL) 5.04 ± 0.86 4.94 ± 0.94 5.19 ± 0.73 0.329
iPTH (pg/mL) 284 (186; 551) 310 (215; 590) 236 (160; 495) 0.259(c)
25 (OH) vit D3 (ng/mL) 19.6 (13.4; 24.8) 20.4 (14.0;24.8) 16.4 (12.4; 24.7) 0.382(c)
1.25(OH)2vit D3 (pg/mL) 11.91 ± 8.25 12.66 ± 9.90 10.78 ± 4.86 0.435
Total cholesterol (mmol/L) 1.64 ± 0.27 1.66 ± 0.28 1.62 ± 0.26 0.593
LDL cholesterol (mmol/L) 0.99 ± 0.26 1.00 ± 0.27 0.97 ± 0.24 0.658
HDL cholesterol (mmol/L) 0.48 ± 0.12 0.46 ± 0.11 0.51 ± 0.12 0.100
Triglycerides (mmol/L) 1.76 (1.30;2.37) 1.58 (1.25;2.25) 2.02 (1.55;3.10) 0.154(c)
Calcium Carbonate n(%) 24 (48%) 16 (54%) 8 (40%) 0.399(a)
Agatston score>400 (n = 42) n = 42 n = 27 n = 15 <0.001(b)
13 (31%) 1 (4%) 12 (80%)
Continuous data are summarized as mean ± standard deviation or median (25th percentile; 75th percentile); SVCS, simple vascular calcification score; HD,
Hemodialysis, Hb, hemoglobin; Ca, calcium; P, phosphorus; iPTH, intact parathyroid hormone
(a)Pearson Chi-Square test
(b)Fisher’s exact test
(c)Mann-Whitney test
other p-values for differences between SVCS<3 and SVCS>3 were obtained by were obtained by Student’s t-test.
https://doi.org/10.1371/journal.pone.0179868.t001
Table 2. Univariable analysis: Association between bone parameters and SVCS.
Variables All patients (n = 50) SVCS <3
(n = 30; 60%)
SVCS 3
(n = 20; 40%)
p value
Bone Volume/Tissue Volume (%) 24.27 ± 8.64 24.92 ± 5.78 23.31 ± 11.83 0.100
Mineralized Bone Volume/Tissue Volume (%) 21.95 ± 7.12 23.56 ± 5.49 19.55 ± 8.63 0.029
Osteoid Volume/Bone Volume (%) 11.09 ± 8.17 12.07 ± 7.82 9.63 ± 8.66 0.437
Osteoid Thickness (μm) 11.42 ± 3.97 11.42 ± 3.11 11.43 ± 5.10 0.989
Mineralization lag time (days) 49.65 ± 42.86 54.36 ± 43.24 42.60 ± 42.40 0.339
Bone formation rate/Bone Surface (mm3/cm2/year) 2.40 (1.65;4.81) 2.59 (1.72;4.82) 2.17(1.49; 4.77) 0.591(a)
Activation frequency (/year) 0.47 (0.27;0.95) 0.27 (.48;.94) 0.47 (0.26; 0.99) 0.968(a)
Low bone turnover n (%) 27 (54%) 15 (50%) 12 (60%) 0.481(b)
High bone turnover n (%) 19 (38%) 12 (40%) 7 (35%) 0.721(b)
Continuous data are summarized as mean ± standard deviation or median (25th percentile; 75th percentile)
(a)Mann-Whitney test
(b)Pearson Chi-Square test
other p-values for differences between SVCS<3 and SVCS>3 were obtained by Student’s t-test.
https://doi.org/10.1371/journal.pone.0179868.t002
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The performance measures of the multivariable regression logistic models are presented in sup-
plemental Table A (S1A Table). When comparing model 1 and models 2 to 4, using the predic-
tiveness curves, model 3 (model 1 + mineralized bone volume) presented a better performance
(Fig 3)
Agreement between SVCS and Agatston score
The study of agreement between SVCS and Agatston score resulted in a Spearman’ s correla-
tion coefficient estimate of 0.71 (95%CI: 0.51, 0.86).
A complementary study of agreement was additionally performed after dichotomizing both
variables. Regarding Agatston score, the cut-point 400 was considered (40), and results of the
minimum p-value approach (Fig 3) identified a SVCS greater than 2 as the best cut-point,
enabling the discretization of this variable as SVCS<3 and SVCS3 (Fig 4). This result is in
accordance with the cut-point previously obtained for higher cardiovascular mortality risk (3,18).
In the group of patients with SVCS3 (Table 1), 12 of 15 patients (80%) had an Agatston
score >400 (p<0.001), and a Cohen’s kappa of 0.79 (95%CI: 0.59, 0.99) was found, indicating
a substantial agreement between the two binary SVCS and Agatston scores (38,39). Addition-
ally, a sensitivity of 0.92 (95%CI: 0.64, 1.00), a specificity of 0.90 (95%CI: 0.73, 0.98), a positive
predictive value of 0.80 (95%CI: 0.55, 0.99), and a negative predictive value of 0.96 (95%CI:
0.79, 0.99), were obtained. The AUC achieved by this binary SVCS score regarding the dis-
crimination of the patients with Agatston score>400 was 0.92 (95%CI: 0.80, 1.00), indicating
an appropriate discrimination ability.
Discussion
In 2006, KDIGO included vascular calcifications in the diagnosis of chronic kidney disease
mineral and bone disorder (CKD-MBD) [11]. The evaluation of the relationship between bone
Table 3. Multivariable logistic regression models. Binary dependent variable: (SVCS<3, SVCS3).
Model 1
OR 95% CI p value
age 1.066 1.013–1.126 0.015
HD duration* 1.131 1.023–1.250 0.017
Model 2 = Model 1 + Bone Volume
age 1.065 1.011–1.121 0.018
HD duration* 1.142 1.028–1.268 0.013
Bone Volume 0.965 0.888–1.049 0.404
Model 3 = Model 1 + Mineralized Bone Volume
age 1.068 1.006–1.133 0.030
HD duration* 1.214 1.060–1.390 0.005
Mineralized Bone volume 0.863 0.766–0.971 0.015
Model 4 = Model 1 + Osteoid Volume
age 1.064 1.010–1.121 0.020
HD duration* 1.142 1.031–1.265 0.011
Osteoid Volume 0.952 0.878–1.033 0.236
OR, odds ratio estimate; HD, hemodialysis; Bone Volume consists of Mineralized Bone Volume and Osteoid
Volume. The different models apply to the same population (n = 50).
*Increased odds of SVCS3 for each six-month increase in HD duration.
https://doi.org/10.1371/journal.pone.0179868.t003
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histomorphometric abnormalities and vascular calcifications was one of the suggested KDIGO
questions for clinical research.
We demonstrate in this study an association between higher mineralized bone volume with
a lower vascular calcification score evaluated by plain X-ray. [3].
Bone is the main reservoir of calcium and phosphate in the organism and acts as a mineral
pool for calcium homeostasis [42]. Bone volume is composed of mineralized bone and non-
mineralized osteoid bone. Hydroxyapatite, a crystalline complex of calcium and phosphate,
constitutes 70% of mineralized bone [42]. The maintenance of the body’s steady state of cal-
cium and phosphorus is the result of the concerted action of intestinal, renal and skeletal regu-
latory mechanisms under tight hormonal control [43]. In dialysis patients, according to the
Braun model [44], bone has a decreased capacity to buffer high blood levels of calcium and
phosphate and, in association with oligo / anuria with reduced calciuria and phosphaturia, the
only escape is the development of vascular calcifications.
In dialysis patients several studies have shown an association between bone disease and vas-
cular calcifications. Low bone turnover [12,14], changes in bone remodelling [13], low bone
volume [15] have been associated with vascular calcifications diagnosed by ultrasonography or
Fig 2. Bone volume and SVCS3. Estimated odds ratios of the association of Bone Volume, Mineralized Bone Volume and Osteoid Volume
with SVCS3 adjusted for age, hemodialysis duration and gender with corresponding confidence intervals and p-values.
https://doi.org/10.1371/journal.pone.0179868.g002
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multislice computed tomography. Bone fractures have been associated with vascular calcifica-
tions evaluated by plain X-ray [17]. Adynamic bone disease has been associated with progres-
sion of coronary calcifications [13]. Lower bone mineral density has been associated with
arterial stiffness [45,46], and with progression of coronary calcifications [16].
The high prevalence of both low bone volume and low bone turnover has been demon-
strated in a study evaluating 630 bone biopsies from dialysis patients [16]. Low bone formation
is the mechanism that links low bone volume to low bone turnover [16]. Our finding of the
association of higher mineralized bone volume with a lower vascular calcifications score is also
in agreement with previous findings of the association of low bone turnover with higher vascu-
lar calcifications scores [12–14]. We expand this observation by identifying mineralized bone
as the major factor of association.
We have previously demonstrated an association between low bone volume with coronary
calcifications [15]. In the present study we have verified an association between the simple
vascular calcification score evaluated in plain X-ray [3] with mineralized bone volume. Our
results highlight the association of mineralized bone volume with vascular calcifications, call-
ing attention for the role of mineralized bone as reservoir of calcium and phosphate and its
possible contribution for the burden of vascular calcifications in dialysis patients.
Computed tomography is the most sensitive method to evaluate the prevalence and pro-
gression of vascular calcifications but, due to the higher cost and the higher radiation dose it is
not suitable to be used in the daily clinical routine.
Fig 3. Predictiveness curves. Predictiveness curves corresponding to the clinical model and to the extended model with: A- BV/TV; B- Md.BV/TV; C- OV/
BV. The dashed grey line below and above the continuous black line (for lower and higher estimated risks, respectively) shows a best performance only for
the model 3, where Md.BV/TV was added to the clinical model.
https://doi.org/10.1371/journal.pone.0179868.g003
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The SVCS is inexpensive, very easy to interpret by the Nephrologist, widely available, and
uses a very low radiation dose. In CKD patients, this score has been associated with all-cause
and cardiovascular mortality [3,18–20], with arterial stiffness [18,46], with low or high ankle
brachial-index [47] and with low bone mineral density [46]. In a large cohort of CKD patients
not on dialysis, this SVCS, but not the Kauppila score, was associated with all-cause and car-
diovascular mortality [20]. We have also verified in the present study that there is a substantial
agreement between an Agatston score > 400 and a SVCS 3.
The main limitation of this study is its observational nature that allows only to show associ-
ations and no cause and effect relationship. The low number of diabetic patients in this study
did not allow to address diabetes as a risk factor. The strength of this study lies in the availabil-
ity of bone biopsies for direct tissue analysis.
In summary, our analysis shows an association of higher mineralized bone volume evalu-
ated in bone biopsies, with a lower vascular calcification score assessed by plain X-ray. The
decreased risk of the association of higher mineralized bone volume with a lower vascular
calcification score suggests that there might be a role for bone in the reduction of the high
cardiovascular risk in hemodialysis patients. This study reinforces the utility of this simple
plain x-ray method to evaluate vascular calcifications for dialysis patients and supports the
hypothesis of the existence of a link between bone mineralization and vascular calcification.
If this hypothesis is correct, it is possible that a therapeutic intervention in bone disease
could have an impact on patient cardiovascular outcomes beyond the beneficial effect on
bone.
Fig 4. Cut-point for SVCS. Chi-square values measuring the association between binary Agatston score and dichotomized SVCS (at potential cut-points).
The maximum chi-squared value occurs at SVCS = 2, enabling the dichotomization of this variable as SVCS<3 and3.
https://doi.org/10.1371/journal.pone.0179868.g004
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